The Executive Guide to Digital Therapeutics in 2026

Every technology budget tells a story, and in digital therapeutics the 2026 story is one of consolidation, evidence, and reimbursement finally catching up with capability. This guide distills what we hear from operators and what the data shows into a working brief for executives.

Start with the problem, not the product

The costliest failures in this category share a root cause: technology purchased before the workflow, staffing, and payment model to absorb it existed. The discipline that separates successful programs is unglamorous - governance first, a narrowly scoped pilot second, measurement third, and scale only when the first three hold.

The market reality

Consider the current numbers: there are 192 FDA-cleared digital therapeutics devices, but only seven are currently eligible for Medicare DMHT payment.

Meanwhile, medicare DMHT patient billing grew from 99 patients in Q1 2025 to 446 by Q3 (our coverage).

Meanwhile, boehringer Ingelheim put $50 million into Click Therapeutics to commercialize its schizophrenia DTx (our coverage).

Meanwhile, a Canadian randomized trial showed digital CBT-I built for adults 65+ meaningfully cut insomnia and anxiety (our coverage).

Questions to ask every vendor

Where is the peer-reviewed or real-world evidence, and on a population like ours? What happens to our data - who trains on it, who profits from it? What does integration actually require from our EHR team? And what is the exit: if we terminate, what do we keep? Vendors comfortable with these questions tend to be the ones still standing in three years.

The bottom line

Digital Therapeutics rewards patient, evidence-driven adopters. Track the category daily on our Digital Therapeutics page and the topic feeds beneath it.